Investing Profile

Niall O’Donnell

InvestorVC

Managing Director at RiverVest Venture Partners

rivervest.com/team-member/nia...Encinitas, California

Your Intro Paths to Niall O’Donnell

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Niall is a member of

University of Oxford Network

416 CONNECTIONS

University of California, San Diego Network

130 CONNECTIONS

UC San Diego Network

120 CONNECTIONS

Johnson & Johnson Network

91 CONNECTIONS

Find Niall O’Donnell on

Current Investing Position

RiverVest Venture Partners Managing Director

Investment Range

$100K - $1M

Sweet Spot

$100K

Investments On Record

Niall O’Donnell is on these Sector & Stage Rankings

Pharmaceuticals (Seed)BioTech (Seed)BioTech (Series A)Pharmaceuticals (Series A)Health IT (Series A)Los Angeles / Southern California Enterprise (Series A)Health & Hospital Services (Series A)Midwest Health IT (Seed)Health & Hospital Services (Seed)Enterprise (Seed)

Niall O’Donnell's Investments On Record (10)

Company	StageDateRound Size	Total Raised
Allotera Therapeutics	Series CAug 2025$120M	$290M
Co-investors: Bali Muralidhar (Abingworth), John McKearn (RiverVest Venture Partners)
Glycomine	Series CApr 2025$120M Series BJun 2021$35M	$150M
Co-investors: Jim Trenkle (Sanofi Ventures), Dominic Schmidt (Advent Life Sciences), Bali Muralidhar (Abingworth)
Atalanta Therapeutics	Series BJan 2025$97M	$210M
Co-investors: Stacie Weninger (F-Prime Capital Partners), Jessica Alston (F-Prime Capital Partners), Stephen Knight (F-Prime Capital (formerly Fidelity Biosciences)), Jason P. Hafler (Sanofi Ventures)
Engrail Therapeutics	Series BMar 2024$170M	$230M
Co-investors: Stacie Weninger (F-Prime Capital Partners), Heath Lukatch (Red Tree Venture Capital), Peter Bisgaard (Nan Fung Life Sciences), Jasper Bos (Forbion)
Reneo Pharmaceuticals	Series BDec 2020$95M Series AMay 2019$50M	$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Bali Muralidhar (Abingworth)
Amplyx Pharmaceuticals	Series CMay 2020$53M Series CAug 2017$67M Series BNov 2015$41M	$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Alex Kahn (Generation Ventures)
Mirum Pharmaceuticals	Series ANov 2018$120M	$120M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Patrick Heron (Frazier Healthcare Partners), Jonathan Leff (Deerfield Management)
Otonomy	Series DApr 2014$49M Series CSep 2013$46M Series BAug 2010$39M Series BAug 2010$39M	$180M
Co-investors: John McKearn (RiverVest Venture Partners), Jay Lichter (Madrona Venture Group), Peter Bisgaard (Nan Fung Life Sciences), Bill Harrington (Osage University Partners (OUP)), Brian Dovey (Domain Associates), Chau Khuong (Catalio Capital Management), Heather Preston (Oxonian Ventures )

Niall O’Donnell's Experience

Post Doctoral Fellow and Researcher Johnson & JohnsonPresent

Managing Director RiverVest Venture PartnersPresent

Interim Chief Medical Officer Lumena Pharmaceuticals Inc.Present

President and Interim CEO Reneo PharmaceuticalsPresent

Niall O’Donnell's Education

University of Oxford MA Natural Sciences (Biochemistry)

The University of Dundee PhD Biochemistry

University of Dundee PhD Biochemistry

UC San Diego Post doc Immunology

University of California, San Diego Post doc Immunology

University of California, San Diego - Rady School of Management MBA Finance & entrepreneurship

Investors who invest with Niall O’Donnell

Scouts & Angels Affiliated With Niall O’Donnell